SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SIGA Technologies reports strong revenue diversification and growth opportunities

SIGA Technologies delivered robust financial results in 2022, showcasing revenue diversification and positive cash flows. With a focus on TPOXX and upcoming FDA submissions, the company is poised for growth. Challenges lie in regulatory hurdles and operational complexities, but opportunities abound in US Government procurement and international sales expansion.

SIGA Technologies projects robust 2023 performance with strategic growth initiatives

SIGA Technologies is poised for a successful 2023, driven by strong financial expectations and product delivery targets. The company's focus on innovation, strategic partnerships, and market expansion positions it well for future growth. Challenges in negotiations, clinical trials, and program scalability require careful management to capitalize on emerging opportunities.

SIGA Technologies projects robust growth in 2023 amidst operational challenges

SIGA Technologies is poised for strong financial performance in the second half of 2023, with revenue expectations and operating income growth.
The company's focus on TPOXX as a key treatment for orthopoxviruses and international sales growth positions it well for future success.
While facing challenges in trial data analysis and CEO transition, SIGA has opportunities for market expansion and revenue diversification.

SIGA Technologies reports solid Q3 earnings amidst packaging challenges

SIGA Technologies is navigating packaging delays and inventory build-up while maintaining a strong financial position. Promising programs and trials indicate growth potential, with opportunities for additional orders and upsells in the EU market.

SIGA Technologies excels in Q4 2023 earnings, eyes innovation and growth

SIGA Technologies delivered impressive financial results in Q4 2023, with strong revenue growth and profitability. Despite facing challenges in contract extensions and manufacturing capacity, the company remains focused on innovation and expansion to drive future growth and value creation.

SIGA Technologies excels in Q1 2024, navigates health challenges

SIGA Technologies delivered a strong performance in Q1 2024, marked by revenue growth, operational efficiency, and strategic advancements. While maintaining a solid financial position, the company faces challenges related to public health concerns and regulatory complexities. Leveraging opportunities in product expansion and global partnerships will be key to sustaining growth and market leadership.

SIGA Technologies reports robust Q2 earnings and global expansion plans

SIGA Technologies' Q2 2024 performance reflects strong revenue growth and financial stability.
The company's focus on diversification, international expansion, and innovation positions it for future success.
Challenges in government contract negotiations and regulatory approvals are balanced by growth opportunities and positive outlook.

SIGA Technologies reports robust Q3 earnings and eyes global expansion

SIGA Technologies' Q3 2024 earnings call reflects strong financial performance, strategic partnerships, and a focus on innovation and market expansion.
The company's commitment to product safety, efficacy, and diverse revenue sources positions it well for future growth and sustained profitability.
While facing challenges in regulatory approvals and market competition, SIGA's financial stability, product credibility, and growth opportunities present a positive outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SIGA Technologies, Inc. (SIGA) Q4 2023 Earnings Call Transcript

• Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023. “In 2023, SIGA had approximately $131 million in product revenues and approximately $84 million of pre-tax operating income,” stated Diem Nguyen, Chief Executive Officer.

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. This represents an increase of $0.15 per share, or 33%, over the cash dividend paid in June 2023.

SIGA Declares Special Cash Dividend of $0.60 Per Share

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 12th, 2024. Participating in the call will be Dr. Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results

NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company's Board of Directors. SIGA's current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024.

SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

SIGA Technologies delivered impressive net sales expectations for Q4 and is working to expand its treatment of human smallpox in new jurisdictions. The company has regulatory approvals for its oral antiviral drug Tpoxx and is exploring expanding its FDA label to include post-exposure prophylaxis against smallpox. SIGA stock has established significant agreements with government entities and international organizations to supply its Tpoxx product, which could drive net sales growth.

SIGA Technologies: Impressive Net Sales Guidance, FDA Approval, And Cheap

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Phillip Louis Gomez - Chief Executive Officer Dennis Hruby - Executive Vice President and Chief Scientific Officer Jay Varma - Executive Vice President and Chief Medical Officer Daniel Luckshire - Executive Vice President and Chief Financial Officer Conference Call Participants Pooya Hemami - Edison Group Paul Saunders - Hatch Capital Operator Welcome to the SIGA business update call. Before we turn the call over to SIGA Management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

SIGA Technologies, Inc. (SIGA) Q3 2023 Earnings Call Transcript

- In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® -

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, November 7th, 2023. Participating on the call will be Phil Gomez, Chief Executive Officer, Dennis Hruby, Chief Scientific Officer, Dr. Jay Varma, Chief Medical Officer and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the creation by the European Commission's DG HERA (Health Emergency Preparedness and Response Authority) of a joint procurement mechanism under which 13 participating countries from the European Union (EU) and the European Free Trade Association (EFTA) can efficiently order oral TPOXX. Based on commitments from EU member countries, it is currently anticipated that $18 million in approximate value of oral TPOXX will be initially ordered by EU countries under this mechanism within the next 60 days. Orders through the joint procurement mechanism will result in country-level procurement of oral TPOXX. Under the joint procurement mechanism, countries in the EU will acquire courses of oral TPOXX in the near term, and be able to efficiently order additional courses of oral TPOXX in the future as long as minimum quantity thresholds are met. Separately, as announced in September of 2022, the European Commission procured oral TPOXX through the funding of a direct purchase. Both transactions were coordinated by SIGA and its international promotion partner, Meridian Medical Technologies, LLC.

SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries

Duolingo

G-III Apparel Group

Lantronix

Virco Mfg.

We have narrowed our search to five Nasdaq Composite-listed stocks that have popped more than 10% in the past month. These are: VIRC, GIII, SIGA, DUOL, LTRX.

Top 5 High-Flying Nasdaq Stocks Defying Index's Recent Turmoil

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO). He will also continue to serve as a director of the SIGA Board of Directors.

SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Phil Gomez - Chief Executive Officer Dennis Hruby - Chief Scientific Officer Dan Luckshire - Chief Financial Officer Conference Call Participants Pooya Hemami - Edison Group Scott Sibley - Equis Group Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

SIGA Technologies, Inc. (SIGA) Q2 2023 Earnings Call Transcript

- In July, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® -

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023

SIGA Technologies (NASDAQ: SIGA ) stock is soaring higher on Friday after the pharmaceutical company secured a government order. That order comes from the U.S. Department of Health and Human Services.

Why Is SIGA Technologies (SIGA) Stock Up 31% Today?

Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOXX under Current Contract reflects continuing global action to enhance smallpox preparedness Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOXX under Current Contract reflects continuing global action to enhance smallpox preparedness

SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®

NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 8th, 2023. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, Dr. Dennis Hruby, Chief Scientific Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results

Cal-Maine Foods

Gulf Resources

In the game of baseball, few events are more frustrating than watching a substandard player make woefully unproductive hacks at the plate, which brings us to the concept of acquiring stocks near 52-week lows. While contrarian sentiment suggests red ink actually means green lights, the opposite tends to be true.

Bottom Fishing: 3 Stocks Near Their 52-Week Lows Angling for a Bounce Back

Inaugural meeting on June 28-30, 2023, to include updates from leading experts on strategies to plan for and address broad range of potential global health risks including biological and viral disease outbreaks. Inaugural meeting on June 28-30, 2023, to include updates from leading experts on strategies to plan for and address broad range of potential global health risks including biological and viral disease outbreaks.

SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium

Evolution Petroleum

Innovative Solutions and Support

While you typically get what you pay for, sometimes, you can get more (in a good way), thus putting a positive spotlight on the these bargain stocks under $10 to buy. Yes, to be completely upfront, these ideas present higher risks than say your typical blue-chip consumer goods manufacturer.

3 Cheap Stocks to Buy for Under $10 in June

TransAlta

United Continental Hlds

Wabash National

Investing in high earnings yield stocks is a compelling strategy for value investors seeking long-term growth opportunities. Unlock profit potential with stocks like WNC, UAL, TAC and SIGA.

4 High Earnings Yield Stocks for a Value-Driven Portfolio

Kennametal

Ligand Pharmaceuticals

Ranger Energy Services

Varex Imaging

VREX, LGND, RNGR, SIGA and KMT have been added to the Zacks Rank #1 (Strong Buy) List on May 5, 2023.

New Strong Buy Stocks for May 5th

Terex

RNGR, TEX and SIGA made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 5, 2023.

Best Value Stocks to Buy for May 5th

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Phil Gomez - CEO Dennis Hruby - Chief Scientific Officer Dan Luckshire - CFO Conference Call Participants Adam McCarter - Edison Group Ralph Weil - R. Weil Investments Operator Welcome to the SIGA Business Update Call.

SIGA Technologies, Inc. (SIGA) Q1 2023 Earnings Call Transcript

NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2023. “First quarter product revenues primarily reflect the sale of oral TPOXX to the U.S. Department of Defense (“DoD”), which marks the third product delivery to the DoD within the past twelve months,” said Phil Gomez, CEO of SIGA.

News for SIGA Technologies Stock (SIGA)